Leerink initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $45 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Promising Outlook for Spyre Therapeutics’ SPY003: Potential Game-Changer in IBD Treatment
- Spyre Therapeutics says first patient dosed in Phase 1 trial of SPY003
- Strategic Potential of Spyre Therapeutics in Combination Therapies for Inflammatory Diseases
- Spyre Therapeutics initiated with an Outperform at Wolfe Research
- Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company Status